Sanofi has returned to U.S. artificial intelligence research biotech Earendil Labs for another significant autoimmune and ...

Last month, the FDA declined to approve Sanofi’s tolebrutinib for a specific form of multiple sclerosis. In a recently ...

GlobalData analyst Vasilis Roumpelakis notes that bispecifics could hold strong potential in the future, but manufacturing ...

Sanofi’s Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetesIf approved, Tzield would be the first ...

Less than two weeks after rejecting Sanofi’s investigational multiple sclerosis drug, the FDA has publicly shared the ...

The company said the regulator accepted a priority review to potentially expand the current age range for its Tzield type-1 ...

Adherence remains a major challenge for the pharmaceutical industry—particularly with self-injected therapies administered at home. Despite substantial investment in traditional patient support ...

Dec 24 (Reuters) - Sanofi (SASY.PA) said on Wednesday it will buy U.S. biotech Dynavax Technologies (DVAX.O) for around $2.2 ...

Sanofi (SNY) to acquire Dynavax Technologies (DVAX) for $15.50 per share in cash, expanding its presence in adult immunization.

The FDA rejected Sanofi's MS drug tolebrutinib, citing liver injury risks, unclear benefits, and trial data that failed to ...

The collaboration with Sanofi focuses on developing bispecific antibodies for autoimmune diseases, leveraging predictive ...

Sanofi could be months away from wider US approval for Tzield, its first-in-class drug for delaying the progression of type 1 ...